Core Insights - Anteris Technologies Global Corp. announced the presentation of one-year clinical outcomes for the DurAVR Transcatheter Heart Valve (THV) at the TCT 2025 conference, highlighting its commitment to innovative heart solutions [1][2]. Company Overview - Anteris Technologies is a global structural heart company focused on designing, developing, and commercializing advanced medical devices aimed at restoring healthy heart function. The company has a significant presence in both Australia and Minneapolis, USA [4]. - The DurAVR THV is the company's lead product, designed in collaboration with leading interventional cardiologists and cardiac surgeons to treat aortic stenosis, a serious condition caused by the narrowing of the aortic valve [5]. Product Details - The DurAVR THV is the first biomimetic valve, engineered to replicate the performance of a healthy human aortic valve and normal aortic blood flow. It is constructed from a single piece of molded ADAPT tissue, which is FDA-cleared and has been used in over 55,000 patients globally [5]. - The DurAVR THV System includes the DurAVR valve, ADAPT tissue, and the balloon-expandable ComASUR Delivery System [5]. Clinical Trials - The clinical outcomes for the DurAVR THV have been encouraging, with over 100 patients implanted. These outcomes will be further assessed in the global pivotal PARADIGM Trial, which is a prospective randomized controlled trial evaluating the safety and effectiveness of the DurAVR THV against existing transcatheter aortic valve replacements [3].

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 9, 2024. Registration No. 333-283414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANTERIS TECHNOLOGIES GLOBAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3842 (Primary Standard Industrial Classification Code Number) 99-1407174 (I ...